Word: developable
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
BIOTERRORISM This is the area where our defenses most need a quick fix. Smallpox vaccines haven't improved much since the 1960s. Until 9/11, few drug companies felt the economic impetus to develop costly antidotes to all-but-conquered infections and ailments. Viagra was a sexier sell. Smallpox was considered to be a "market you hope will never exist," says Alan Goldhammer of the Pharmaceutical Research and Manufacturers of America...
...improve our medical defenses against biowarfare by launching Project BioShield last January. Its aim is to make Washington the guaranteed buyer for vaccines and drugs to combat bioterrorism. If it gets under way next month as planned--Senate passage still awaits--billions of federal dollars will be available to develop, purchase and stockpile those drugs over the next 10 years. The exact dollar amount remains unclear, but when the House approved Project BioShield in July by a vote of 421-2, it moved to cap the figure at $5.6 billion over 10 years, not the $6 billion Bush had first...
That sounds like a lot of cash, but when it can cost, say, $900 million to develop just one drug, according to the Tufts Center for the Study of Drug Development, the money goes fast. The standard drug-approval process poses a problem, and Washington hopes to reduce the time and expense by simplifying the approval process for pharmaceuticals useful against bioterrorism. Because things like radiation poisoning or plague occur rarely, it's difficult to find human subjects to test new cures. The FDA has eased the rules for bioterrorism-related drugs, allowing tests for effectiveness to be conducted entirely...
...selling her ImClone stock. In June, ImClone reported that its drug Erbitux, in combination with chemotherapy, reduced tumor growth in the colon up to 55%, putting the controversial drug on track for FDA consideration. Erbitux targets cancer cells by blocking their ability to absorb growth factors they need to develop. Trials for treating other tumors, including those in the lung, head and neck, are under...
...signed on to build a better faculty and curriculum, to advance work that he had begun earlier in his career to develop a broader and more diverse student body. He did not relish that time,” Stephen Ford said...